Genotype-guided treatment of oral P2Y12 inhibitors: where do we stand? [0.03%]
基因指导的口服P2Y12抑制剂治疗：我们目前处在什么位置？
Daniel Mf Claassens,Jurriën M Ten Berg
Daniel Mf Claassens
The emergent phenomenon of aspirin resistance: insights from genetic association studies [0.03%]
血小板对阿司匹林抵抗的遗传学研究及其展望
Márcia Ferreira,Margarida Freitas-Silva,Joana Assis et al.
Márcia Ferreira et al.
Despite the clinical benefits of aspirin, the interindividual variation in response to this antiplatelet drug is considerable. The manifestation of aspirin resistance (AR) is frequently observed, although this complex process remains poorly...
Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data [0.03%]
精准医疗时代的药物基因组学：大数据时代的挑战与展望
Dragan Primorac,Lidija Bach-Rojecky,Dalia Vađunec et al.
Dragan Primorac et al.
Pharmacogenomics (PGx) is one of the core elements of personalized medicine. PGx information reduces the likelihood of adverse drug reactions and optimizes therapeutic efficacy. St Catherine Specialty Hospital in Zagreb/Zabok, Croatia has i...
Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients [0.03%]
凝血酶抑制剂华法林在老年患者中的用药量受CYP2C9、VKORC1、ApoE和ABCB1多态性影响的研究
Wenyan Li,Ping Zhao,Liwen Chen et al.
Wenyan Li et al.
Aim: To analyze the impact of nongenetic factors and gene polymorphisms on warfarin dose requirements in elderly Shanghai Han Chinese patients. Materials & methods: Genotypes of CYP2C9 (rs1799853 and rs1057910), FPGS (rs7856096), ApoE (rs74...
A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention [0.03%]
CDH13/CDH15基因在首次经皮冠状动脉介入治疗后重复血运重建中的潜在作用
Qian Xiang,Zhiyan Liu,Yun Lu et al.
Qian Xiang et al.
Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat rev...
Palle Duun Rohde,Torsten Nygaard Kristensen
Palle Duun Rohde
Germline variants and response to systemic therapy in advanced prostate cancer [0.03%]
胚细胞变异与晚期前列腺癌全身治疗疗效的关系
Eric Johnson,Roberto Nussenzveig,Neeraj Agarwal et al.
Eric Johnson et al.
Our current understanding of prostate cancer pharmacogenomics is growing at a rapid pace. Apart from evaluating relevant biomarkers and genomic alterations in tumor tissues, an increasing focus is being placed on decoding the impact of germ...
Cost-effectiveness of CYP2C19 LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome [0.03%]
在中国急性冠脉综合征患者中根据CYP2C19功能缺失型等位基因指导的抗血小板治疗的成本效果分析
Yu Fu,Xin-Yi Zhang,Si-Bei Qin et al.
Yu Fu et al.
Aim: This study aimed to evaluate the cost-effectiveness of CYP2C19 loss-of-function(LOF) allele-guided antiplatelet therapy compared with the universal use of clopidogrel or ticagrelor among Chinese patients with acute coronary syndrome un...
Personalized pediatric anesthesia and pain management: problem-based review [0.03%]
个性化小儿麻醉与镇痛管理：基于问题的回顾
Senthil Packiasabapathy,Valluvan Rangasamy,Nicole Horn et al.
Senthil Packiasabapathy et al.
Pharmacogenetics, the genetic influence on the interpersonal variability in drug response, has enabled tailored pharmacotherapy and emerging 'personalized medicine.' Although oncology spearheaded the clinical implementation of personalized ...
CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy [0.03%]
CYP3A5*3和CYP2C8*3基因多态性影响他克莫司的暴露量及其治疗效果
Fabiana Dalla Vecchia Genvigir,Antony Brayan Campos-Salazar,Claudia Rosso Felipe et al.
Fabiana Dalla Vecchia Genvigir et al.
Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined ...